Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001820817 | Thyroid | PTC | peptidyl-proline modification | 42/5968 | 58/18723 | 2.71e-10 | 8.91e-09 | 42 |
GO:0061077112 | Thyroid | PTC | chaperone-mediated protein folding | 46/5968 | 67/18723 | 6.91e-10 | 2.08e-08 | 46 |
GO:0010639112 | Thyroid | PTC | negative regulation of organelle organization | 163/5968 | 348/18723 | 3.04e-09 | 8.39e-08 | 163 |
GO:007050717 | Thyroid | PTC | regulation of microtubule cytoskeleton organization | 80/5968 | 148/18723 | 1.79e-08 | 4.19e-07 | 80 |
GO:0010975110 | Thyroid | PTC | regulation of neuron projection development | 194/5968 | 445/18723 | 1.05e-07 | 2.08e-06 | 194 |
GO:00004137 | Thyroid | PTC | protein peptidyl-prolyl isomerization | 30/5968 | 42/18723 | 1.65e-07 | 3.13e-06 | 30 |
GO:0031333112 | Thyroid | PTC | negative regulation of protein-containing complex assembly | 68/5968 | 141/18723 | 3.61e-05 | 3.37e-04 | 68 |
GO:1902904111 | Thyroid | PTC | negative regulation of supramolecular fiber organization | 78/5968 | 167/18723 | 4.16e-05 | 3.80e-04 | 78 |
GO:003111316 | Thyroid | PTC | regulation of microtubule polymerization | 32/5968 | 55/18723 | 5.03e-05 | 4.47e-04 | 32 |
GO:00328866 | Thyroid | PTC | regulation of microtubule-based process | 105/5968 | 240/18723 | 6.91e-05 | 6.03e-04 | 105 |
GO:00467858 | Thyroid | PTC | microtubule polymerization | 43/5968 | 83/18723 | 1.26e-04 | 9.98e-04 | 43 |
GO:00313459 | Thyroid | PTC | negative regulation of cell projection organization | 83/5968 | 186/18723 | 1.72e-04 | 1.32e-03 | 83 |
GO:00311105 | Thyroid | PTC | regulation of microtubule polymerization or depolymerization | 44/5968 | 88/18723 | 3.00e-04 | 2.11e-03 | 44 |
GO:005149419 | Thyroid | PTC | negative regulation of cytoskeleton organization | 73/5968 | 163/18723 | 3.59e-04 | 2.44e-03 | 73 |
GO:00109778 | Thyroid | PTC | negative regulation of neuron projection development | 63/5968 | 137/18723 | 3.70e-04 | 2.50e-03 | 63 |
GO:00311096 | Thyroid | PTC | microtubule polymerization or depolymerization | 57/5968 | 122/18723 | 4.19e-04 | 2.81e-03 | 57 |
GO:003227218 | Thyroid | PTC | negative regulation of protein polymerization | 38/5968 | 80/18723 | 2.49e-03 | 1.29e-02 | 38 |
GO:0031115 | Thyroid | PTC | negative regulation of microtubule polymerization | 9/5968 | 14/18723 | 1.27e-02 | 4.92e-02 | 9 |
GO:000645733 | Thyroid | ATC | protein folding | 140/6293 | 212/18723 | 3.46e-22 | 8.09e-20 | 140 |
GO:1902903210 | Thyroid | ATC | regulation of supramolecular fiber organization | 210/6293 | 383/18723 | 6.20e-18 | 7.54e-16 | 210 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0491520 | Cervix | CC | Estrogen signaling pathway | 44/1267 | 138/8465 | 3.55e-07 | 3.97e-06 | 2.35e-06 | 44 |
hsa04915110 | Cervix | CC | Estrogen signaling pathway | 44/1267 | 138/8465 | 3.55e-07 | 3.97e-06 | 2.35e-06 | 44 |
hsa04915 | Colorectum | SER | Estrogen signaling pathway | 38/1580 | 138/8465 | 6.51e-03 | 3.68e-02 | 2.67e-02 | 38 |
hsa049151 | Colorectum | SER | Estrogen signaling pathway | 38/1580 | 138/8465 | 6.51e-03 | 3.68e-02 | 2.67e-02 | 38 |
hsa049152 | Colorectum | MSS | Estrogen signaling pathway | 48/1875 | 138/8465 | 4.23e-04 | 3.08e-03 | 1.89e-03 | 48 |
hsa049153 | Colorectum | MSS | Estrogen signaling pathway | 48/1875 | 138/8465 | 4.23e-04 | 3.08e-03 | 1.89e-03 | 48 |
hsa049154 | Colorectum | CRC | Estrogen signaling pathway | 29/1091 | 138/8465 | 4.83e-03 | 2.66e-02 | 1.80e-02 | 29 |
hsa049155 | Colorectum | CRC | Estrogen signaling pathway | 29/1091 | 138/8465 | 4.83e-03 | 2.66e-02 | 1.80e-02 | 29 |
hsa0491529 | Oral cavity | EOLP | Estrogen signaling pathway | 38/1218 | 138/8465 | 3.78e-05 | 1.82e-04 | 1.07e-04 | 38 |
hsa04915113 | Oral cavity | EOLP | Estrogen signaling pathway | 38/1218 | 138/8465 | 3.78e-05 | 1.82e-04 | 1.07e-04 | 38 |
hsa0491527 | Prostate | BPH | Estrogen signaling pathway | 48/1718 | 138/8465 | 4.60e-05 | 3.16e-04 | 1.96e-04 | 48 |
hsa04915112 | Prostate | BPH | Estrogen signaling pathway | 48/1718 | 138/8465 | 4.60e-05 | 3.16e-04 | 1.96e-04 | 48 |
hsa0491528 | Prostate | Tumor | Estrogen signaling pathway | 48/1791 | 138/8465 | 1.36e-04 | 8.33e-04 | 5.17e-04 | 48 |
hsa0491536 | Prostate | Tumor | Estrogen signaling pathway | 48/1791 | 138/8465 | 1.36e-04 | 8.33e-04 | 5.17e-04 | 48 |
hsa0491512 | Stomach | GC | Estrogen signaling pathway | 23/708 | 138/8465 | 1.02e-03 | 7.44e-03 | 5.23e-03 | 23 |
hsa0491513 | Stomach | GC | Estrogen signaling pathway | 23/708 | 138/8465 | 1.02e-03 | 7.44e-03 | 5.23e-03 | 23 |
hsa0491521 | Stomach | CAG with IM | Estrogen signaling pathway | 21/640 | 138/8465 | 1.53e-03 | 1.01e-02 | 7.10e-03 | 21 |
hsa0491531 | Stomach | CAG with IM | Estrogen signaling pathway | 21/640 | 138/8465 | 1.53e-03 | 1.01e-02 | 7.10e-03 | 21 |
hsa0491541 | Stomach | CSG | Estrogen signaling pathway | 20/633 | 138/8465 | 3.10e-03 | 1.88e-02 | 1.35e-02 | 20 |
hsa0491551 | Stomach | CSG | Estrogen signaling pathway | 20/633 | 138/8465 | 3.10e-03 | 1.88e-02 | 1.35e-02 | 20 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FKBP4 | SNV | Missense_Mutation | | c.557G>A | p.Arg186Gln | p.R186Q | Q02790 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
FKBP4 | SNV | Missense_Mutation | novel | c.1223N>G | p.Lys408Arg | p.K408R | Q02790 | protein_coding | tolerated(0.26) | benign(0.159) | TCGA-A7-A4SD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
FKBP4 | SNV | Missense_Mutation | novel | c.766N>C | p.Lys256Gln | p.K256Q | Q02790 | protein_coding | deleterious(0) | possibly_damaging(0.881) | TCGA-BH-A0HU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
FKBP4 | SNV | Missense_Mutation | | c.1108G>A | p.Glu370Lys | p.E370K | Q02790 | protein_coding | deleterious(0.04) | benign(0.058) | TCGA-EA-A1QS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
FKBP4 | SNV | Missense_Mutation | | c.823G>C | p.Glu275Gln | p.E275Q | Q02790 | protein_coding | tolerated(0.08) | benign(0.428) | TCGA-EK-A2H0-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
FKBP4 | SNV | Missense_Mutation | | c.26C>T | p.Thr9Ile | p.T9I | Q02790 | protein_coding | tolerated(0.18) | benign(0.017) | TCGA-Q1-A73P-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
FKBP4 | SNV | Missense_Mutation | | c.823G>C | p.Glu275Gln | p.E275Q | Q02790 | protein_coding | tolerated(0.08) | benign(0.428) | TCGA-ZJ-A8QQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
FKBP4 | SNV | Missense_Mutation | novel | c.976G>T | p.Ala326Ser | p.A326S | Q02790 | protein_coding | deleterious(0.04) | possibly_damaging(0.59) | TCGA-ZJ-AAX8-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
FKBP4 | insertion | Frame_Shift_Ins | novel | c.372dupC | p.Asn125GlnfsTer7 | p.N125Qfs*7 | Q02790 | protein_coding | | | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
FKBP4 | SNV | Missense_Mutation | rs766636474 | c.1343N>T | p.Thr448Met | p.T448M | Q02790 | protein_coding | tolerated_low_confidence(0.16) | benign(0) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |